Dernière mise à jour: Août 17, 2026
Ces cellules souches peuvent s'auto-renouveler et sont responsables de la formation de cellules cancéreuses qui composent la tumeur..
Le cancer du foie est la deuxième cause de décès liés au cancer dans le monde.
Le cancer primitif du foie le plus courant chez les adultes est appelé carcinome hépatocellulaire. (CHC), et représente environ 780,000 deaths every year.
Even with advanced surgical treatments or transplantation, the 5-year survival rate for HCC patients remains poor due to frequent recurrence.
Maintenant, ..researchers has demonstrated a potential method for treating advanced liver cancers like HCC. ..Scientists showed that a class of small molecule drugs that target the JAK/STAT signalling pathway could be used to fight against the disease.
“Targeting molecular mechanisms that drive chemoresistance has shown success in clinical trials for other diseases. Donc, such targeted approaches can be potentially useful as adjuvant therapies to improve clinical outcomes of HCC patients.
Inhibiting the JAK/STAT signalling pathway
The JAK/STAT signalling pathway is an important set of proteins that control a wide range of biological functions, including immune responses and cellular development. This pathway typically responds to external cellular cues to turn on specific sets of genes that help cells properly develop or allow the immune system to fight off infections. En tant que tel, if the JAK/STAT signalling pathway somehow goes awry, it can lead to the formation of tumours.
In their study, the NUS team targeted the JAK/STAT pathway to inhibit its action in tumour formation. They showed that a subpopulation of cancer ‘stem-like’ cells are sensitive to a class of small molecule drugs that inhibit the JAK/STAT pathway. Ces cellules souches peuvent s'auto-renouveler et sont responsables de la formation de cellules cancéreuses qui composent la tumeur..
“We can now potentially use small molecule compounds to target these specific small population of cancer stem-like cells that are often the cause of tumour recurrence.”
Small molecule drug candidates effective in reducing cancer progression
The researchers were able to isolate these tumour-initiating cancer cells that are often the culprits of therapy resistance that leads to cancer relapse. They found that an important cancer pathway, known as the JAK/STAT signalling pathway, was enriched in this cancer stem-like population of cells.
Dans cette étude, JAK/STAT inhibitors targeting cancer stem-like cells were able to effectively reduce cancer progression in preclinical models of liver cancer. The NUS team found that the tumour forming ability was reduced by 50 per cent after drug treatment.
Next steps
These findings provide increased support that JAK/STAT-based therapies targeting cancer stem-like cells are important for more effective treatment outcomes against liver cancer.
r the treatment of other solid cancers.
Story Source:
ScienceDaily. ScienceDaily, 9 Octobre 2019. <www.sciencedaily.com/releases/2019/10/191009093953.htm>.
Examen de cas scientifiques
Souhaitez-vous savoir si les programmes cliniques actuels, développements récents en recherche, ou des approches émergentes peuvent être adapté à votre situation individuelle?
Partagez votre question avec notre équipe de recherche scientifique et recevez informations axées sur les domaines de recherche en cours qui peuvent être pertinent pour votre cas.
- Examen des informations que vous fournissez
- Informations pertinentes sur la recherche et les programmes cliniques
- Une réponse claire et adaptée à votre situation
Aucune obligation. Votre question sera examinée de manière confidentielle.
Informations pédagogiques et de recherche uniquement. Ce service ne constituer un avis médical, diagnostic, ordonnance, ou un personnalisé recommandation de traitement.
